Novartis Ag

Frédéric Stauffer

Pascal Furet

Clive McCarthy

Carlos Garcia-Echeverria

Robin Alec Fairhurst

Giorgio Caravatti

Heinrich Rueeger

Robert Mah

Frederic Zecri

Hans-Georg Capraro

Frank Hans Seiler

Nigel Graham Cooke

Joseph Schoepfer

Frank Stowasser

Carsten Spanka

Anette Von Matt

Ian Lewis

Patricia Imbach

Nicolas Soldermann

Gregory John Hollingworth

Christina Hebach

Alexander Baxter Smith

Romain Wolf

Ross Strang

Paulo Antonio Fernandes Gomes Dos Santos

Frank Stephan Kalthoff

Klemens Hoegenauer

Nicola Tuffilli

Melanie Stang

Christian Ragot

Christoph Kalis

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Oxazolidin-2-one compounds and uses thereof

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

3-Methyl-imidazo[1,2-b]pyridazine derivatives

The invention relates to the use of 1H-imidazo[4,5-]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-]quinolinone derivatives.

[object Object]

The invention relates to methods of treatment of a proliferative disease which responds to inhibition of PI3-Kinase-related protein kinases, particularly the PI3-kinase, by administration of a novel organic compound of formula (I) to a human or animal requiring such treatment; and methods of treatment of inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease, by administration of such compound.

1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors

The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors

1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

Growing community of inventors

Hesingue, France

Frédéric Stauffer